A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
A2 Biotherapeutics Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
Seagen Inc.
Novartis
Var2 Pharmaceuticals
City of Hope Medical Center
A2 Biotherapeutics Inc.
Elicio Therapeutics
ModeX Therapeutics, An OPKO Health Company
Shanghai Cingularbio Co. Ltd
Columbia University
University of Arizona
Stanford University
Peter MacCallum Cancer Centre, Australia
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chongqing Precision Biotech Co., Ltd
UTC Therapeutics Inc.
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Novartis
MacroGenics
Wake Forest University Health Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
City of Hope Medical Center
Stanford University
Instituto do Cancer do Estado de São Paulo
Stanford University
Johns Hopkins Bloomberg School of Public Health
Northwestern University
Fox Chase Cancer Center
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center